 |
 |
 |
|
HOME > Investor Relations > New Drug Pipeline
 |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application | Development with | Originator | |
|---|---|---|---|
| Approved | |||
| Clarith tab. 200 | Eradication by concomitant therapy* of H. pylori in gastric MALT lymphoma, the stomach after endoscopic resection of early stage gastric cancer, and idiopathic thrombocytopenic purpura <Additional indication> |
Joint application with 9 companies | Taisho |
| Filed for application | |||
| CT-081** (Oral) |
Osteoporosis | Chugai Pharmaceutical | Chugai Pharmaceutical |
| Phase 2/3 | |||
| CT-064*** (Injection) |
Osteoporosis | Chugai Pharmaceutical | Roche |
| Phase 2 | |||
| TT-063 (Topical) |
Osteoarthritis, scapulohumeral periarthritis, myalgia and other conditions | Tokuhon | Tokuhon |
| NT-702 (Oral) |
Asthma | Nissan Chemical | Nissan Chemical |
| Intermittent claudication caused by ASO**** | |||
| CT-064*** (Oral) |
Osteoporosis | Chugai Pharmaceutical | Roche |
| TS-071 (Oral) |
Type 1 and 2 diabetes | In-house | Taisho |
| Palux (Injection) |
Intermittent claudication caused by SCS***** <Additional indication> |
In-house | Taisho/ Mitsubishi Tanabe |
*Concomitant therapy: Consists of a proton pump inhibitor (lansoprazole, omeprazole, and rabeprazole sodium), amoxicillin hydrate, and clarithromycin
**CT-081: Chugai Pharmaceutical development code: ED-71
***CT-064: Chugai Pharmaceutical development code: R484
****ASO: Arteriosclerosis obliterans
*****SCS: Spinal canal stenosis
